



Katten Represented Sawai Group in its Sale of Upsher-Smith to Bora Pharmaceutical Holdings

January 23, 2024

In a complex transaction announced on January 16, Katten represented generic medicines manufacturer Sawai Pharmaceutical in connection with the sale of Upsher-Smith Laboratories, a manufacturer of generic and specialty branded drugs based in Minnesota. Sumitomo Corporation of Americas, a co-investor in Sawai America LLC, will transfer its interests to Bora as part of the transaction.

The deal, valued at \$210 million, is subject to approval from regulators.

The Katten team representing Sawai, Sumitomo, and Upsher-Smith was led by Intellectual Property Partner Brian Sodikoff, co-chair of Patent Litigation, along with Antitrust and Competition Partner James Calder, Litigation Partner Jonathan Rotenberg and Associate Zachary Beal.

["Notice of Transfer \(Sale of Shares/Equity Interests\) of Sawai's U.S. Subsidiary / Sub-subsidiary," Upsher-Smith, January 16, 2024](#)

["Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for \\$210 Million in Transaction to Fuel Global Expansion," Bora Pharmaceuticals, January 16, 2024](#)

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Brian Sodikoff

+1.312.902.5462

brian.sodikoff@katten.com



Jonathan Rotenberg

+1.212.940.6405

jonathan.rotenberg@katten.com



Zachary S. Beal

+1.212.940.6348

zachary.beal@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2026 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.